A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)

Polycystic Ovary Syndrome (PCOS) Clinical Trial

— SPIOMET4HEALTH  

Official title:

A Phase II, Randomised, Multi-centric, Multi-national Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) for Adolescent Girls and Young Adult Women (AYAs) With Polycystic Ovary Syndrome (PCOS)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05394142
• Other study ID #: SPIOMET4HEALTH
• Secondary ID: 2021-003177-58
• Status: Recruiting
• Phase: Phase 2
• Start date: May 24, 2022
• Est. completion date: April 2025

Study information

• Verified date: April 2024
• Source: Fundació Sant Joan de Déu
• Contact: Rita Malpique, PhD
• Phone: +34936 00 97 51
• Email: rita.malpique[@]sjd.es
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase II clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone and Metformin (SPIOMET) for adolescent girls and young adult women with polycystic ovary syndrome.

Study description: Currently, there is no European Medicines Agency /U.S. Food and Drug Administration (FDA)-approved therapy for polycystic ovary syndrome in adolescent girls and young adult women. Oral contraceptives (OCs) are prescribed off-label to approximately 98% of AYAs with PCOS, including those without pregnancy risk. OCs alleviate key symptoms by inducing a pharmacological combination of anovulatory subfertility, regular pseudo-menses, and extreme elevations of sex hormone-binding globulin (SHBG), but OCs do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility and possibly, for lifelong co-morbidities.

Given the key role of hepato-visceral fat excess in the pathogenesis of PCOS, the prime aim of the treatment should be to achieve a preferential loss of central fat, which should in turn normalise the entire PCOS phenotype. Recent evidence disclosed that a treatment consisting of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), with different modes of action], and one mixed anti-androgen and anti-mineralocorticoid (spironolactone), was superior to an OC in normalising the PCOS phenotype, including ovulation rates and hepato-visceral fat.

The study's main goals are to assess the efficacy, tolerability and safety of a new treatment (SPIOMET) for adolescent girls and young adult women with polycistic ovarian syndrome; the comparison (in this order) of each SPIOMET, spironolactone and pioglitazone (SPIO) and PIO over placebo; and in addition, the comparison of SPIOMET over PIO and over SPIO (in this order).

Primary Objective: To test the efficacy of SPIOMET in normalising ovulation rate in adolescents and young adult women with PCOS.

Secondary Objectives: To test the efficacy of SPIOMET in normalising the endocrine-metabolic status, to describe the drug safety profile and to assess the adherence and subjective acceptability, as well as the quality of life of the participating subjects.

Description:

This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase II clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone and Metformin (SPIOMET) for adolescent girls and young adult women (AYAs) with polycystic ovary syndrome (PCOS).

Study description: Currently, there is no European Medicines Agency (EMA)/U.S. Food and Drug Administration (FDA)-approved therapy for PCOS in AYAs. Oral contraceptives (OCs) are prescribed off-label to approximately 98% of AYAs with PCOS, including those without pregnancy risk. OCs alleviate key symptoms by inducing a pharmacological combination of anovulatory subfertility, regular pseudo-menses, and extreme elevations of sex hormone-binding globulin (SHBG), but OCs do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility and possibly, for lifelong co-morbidities.

Given the key role of hepato-visceral fat excess in the pathogenesis of PCOS, the prime aim of the treatment should be to achieve a preferential loss of central fat, which should in turn normalise the entire PCOS phenotype. Recent evidence disclosed that a treatment consisting of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), with different modes of action], and one mixed anti-androgen and anti-mineralocorticoid (spironolactone), was superior to an OC in normalising the PCOS phenotype, including ovulation rates and hepato-visceral fat.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 364
• Est. completion date: April 2025
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 12 Years to 23 Years

Eligibility

Inclusion Criteria:

1. Age range within the AYAs category (> 12.0 years and = 23.9 years at study start) (96); Given that another inclusion criterium is gynaecological age (years elapsed since menarche) of 2 years or more, and that menarche before age 10.0 years is an exclusion criterium (please see exclusion criteria below), the youngest participant will be older than 12.0 years at study start (97). The upper age limit at study start is set at 23.9 years (thus, 24.9 years when the active treatment ends, see section 7. Conduct), in order to avoid early dropouts due to an increase in the prevalence of pregnancy wish beyond that age in most European countries;

2. Gynaecological age of 2 years or more;

3. Clinical androgen excess, as defined by the presence of hirsutism (modified Ferriman-Gallwey score = 4) (17,98) and/or inflammatory acne (Leeds scale) unresponsive to medications (3,95,99). The scarce normative data existing in adolescents suggest that an adult level of hirsutism is reached around 2 years after menarche (100);

4. Biochemical androgen excess, as defined by increased total testosterone (=50 ng/dL), and/or a FAI higher than 3.5 [FAI, total testosterone (nmol/L) x 100/SHBG (nmol/L)], in the follicular phase of the cycle (days 3-7) or after 2 months of amenorrhea (3,100,101); Measurements of total testosterone and/or FAI are the most recommended assessments to screen for hyperandrogenaemia (3,19,95,102). Serum testosterone attains adult levels shortly after menarche; thus, an elevation of serum testosterone concentrations and/or FAI above adult norms and assessed in reliable reference laboratories constitutes biochemical evidence of hyperandrogenism (3,19,95,100). It is accepted that this upper limit can be set at 45 ng/dL for testosterone and at 3.5 for FAI (3,95,100,101,102,103). Direct free testosterone assays, such as radiometric or enzyme-linked assays, preferably should not be used in the assessment of biochemical hyperandrogenism, as they demonstrate poor sensitivity, accuracy and precision (17);

5. Menstrual irregularity, as defined by = 8 menses per year corresponding to an average inter-menstrual time of =45 days (3,95,100); Most adolescents establish a menstrual interval of 20-45 days within the first 2 years after menarche (3,95). Three years after menarche, the 95th percentile for cycle length is 43.6 days (104); thus, cycles longer than 45 days (<8 periods/year) at or beyond this gynaecological age are considered abnormal and are evidence of oligo-anovulation;

6. Written informed consent obtained from the patient, or assent from the patient and consent by the parents or the legally acceptable representative if she is a minor (for details, see section 7. Conduct, under informed consent).

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Polycystic Ovary Syndrome
• Polycystic Ovary Syndrome (PCOS)
• Syndrome

Intervention

Drug:
• Placebo
Comparator arm with placebo
• Pioglitazone
Pioglitazone 7.5 mg/day
• Spironolactone
Spironolactone 50 mg/day
• Metformin
Metformin 850 mg/day

Locations

Country	Name	City	State
Austria	Universitätsklinik für Innere Medizin	Graz
Denmark	Odense University Hospital (UNIODE)	Odense
Italy	Azienda Ospedaliero Universitaria di Bologna	Bologna
Norway	St. Olavs Hospital	Trondheim
Spain	Hospital Sant Joan de Deu	Esplugues De Llobregat
Spain	Hospital Universitari de Girona Dr. Trueta	Girona
Turkey	Istanbul Faculty of Medicine Topkapi	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Fundació Sant Joan de Déu

Countries where clinical trial is conducted

Austria,  Denmark,  Italy,  Norway,  Spain,  Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	On-treatment ovulation rate.	On-treatment ovulation rate.	Following end of each two 12-week on-treatment periods (month 0-3 and month 9-12)
Primary	Post-treatment ovulation rate.	Post-treatment ovulation rate.	Following the end of post-treatment period (month 12-15)
Secondary	Clinical variable: hirsutism	Presence of hirsutism as measured by the modified Ferriman & Gallwey score	Every 3 months from study start to study completion (estimated 18 months)
Secondary	Clinical variable: Acne	Presence of Acne as evaluated using the Leeds Acne Grading Scale	Every 3 months from study start to study completion (estimated 18 months)
Secondary	Clinical variable: menstrual regularity	Assessment of the menstrual regularity	Every 3 months from study start to study completion (estimated 18 months)
Secondary	Circulating androgens	Assessment by measurement of circulating androgens	Every 3 months from study start to study completion (estimated 18 months)
Secondary	Lipids	Assessment by measurement of total cholesterol, low-density lipoprotein (LDL-cholesterol), high-density lipoprotein (HDL- cholesterol), triglycerides;	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	Insulinaemia	Fasting and 2 hours after a 75-gr oral glucose load [oral glucose tolerance test (oGTT). Estimation of insulin resistance from fasting insulin and glucose levels using the homeostasis model assessment (HOMA);	Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary	Inflammation markers	Inflammation markers	Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary	Insulin sensitivity	Insulin sensitivity	Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary	Ultra-sensitive C-reactive protein (us-CRP);	Ultra-sensitive C-reactive protein (us-CRP);	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	Growth-and- differentiation factor-15 (GDF15);	Growth-and- differentiation factor-15 (GDF15);	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	High molecular weight adiponectin (HMW-adip),	High molecular weight adiponectin (HMW-adip),	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	C-X-C motif chemokine ligand 14 (CXCL14) (69,81);	C-X-C motif chemokine ligand 14 (CXCL14) (69,81);	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	Epigenetic variable	Circulating microRNA 451-a (miR-451a) concentrations (88);	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	Imaging: Cardiovascular risk	As measured by ultrasound	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	Imaging: Body composition	As measured by dual-energy X-ray absorptiometry (DXA)	Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary	Imaging: Abdominal fat distribution (subcutaneous and visceral)	As measured by MRI	Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary	Imaging:hepatic fat	As measured by MRI	Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary	Abdominal fat distribution	Waist circumference, Waist to hip ratio (WHR), and hepatic fat by MRI	Baseline and at the end of treatment (month 12) and 6 months after treatment
Secondary	Weight	Weight measurement	Every 3 months from study start to study completion (estimated 18 months)
Secondary	Improvement of co-morbidities	Improvement of co-morbidities	Every 3 months from study start to study completion (estimated 18 months)
Secondary	Improvement of health behaviour	Improvement of health behaviour	Every 3 months from study start to study completion (estimated 18 months)
Secondary	Improvement of health-related quality of life (HRQoL)	As reported by the patient	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	Safety laboratory tests	Blood count, electrolyte panel, urea, alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyltransferase (GGT), creatinine, vitamin B12 and folic acid;	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	Adverse events (AEs)	As reported by the patient	Every 3 months from study start to study completion (estimated 18 months)
Secondary	Adherence	Adherence will be calculated as the ratio between the number of tablets prescribed and dispensed for the period between hospital appointments and the number of tablets returned by the patient at the following appointment;	Every 3 months from study start to study completion (estimated 18 months)
Secondary	Acceptability of the treatment	Acceptability of the tablet by the study patients	Every 3 months from study start to study completion (estimated 18 months)
Secondary	PROMs (patient-reported outcomes)	Questionnaire SF-36	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	PROMs (patient-reported outcomes)	Questionnaire PCOSQ	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	HRQoL (health-related quality of life)	Questionnaire SF-36	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Secondary	HRQoL (health-related quality of life)	Questionnaire PCOSQ	Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment